Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.

Leukemia & lymphoma - 1 Aug 2022

Karantanos Theodoros, Tsai Hua-Ling, Gondek Lukasz P, DeZern Amy E, Ghiaur Gabriel, Dalton W Brian, Gojo Ivana, Prince Gabrielle T, Webster Jonathan, Ambinder Alexander, Smith B Douglas, Levis Mark J, Varadhan Ravi, Jones Richard J, Jain Tania

Abstract excerpt

There are currently no known predictors of myelodysplastic syndrome (MDS)/myeloproliferative overlap neoplasm (MPN) patients' response to hypomethylating agents (HMA). Forty-three patients with MDS/MPN who were treated with HMA during chronic phase and had next-generation sequencing using the established 63-genes panel were identified. Complete and partial remission and marrow response were assessed based on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factor Alpha 2 Subunit

Share to Genomics

Share to Mutation

Share to Myelodysplastic-Myeloproliferative Diseases

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35379077
DOI: 10.1080/10428194.2022.2057488
PMCID: PMC9847567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.PMID 35379077Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.Semantic proximity Read ↗

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.Semantic proximity Read ↗

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.